Survival 80% or Higher with Allogeneic HCT after Failed Autologous HCT for Lymphoma

In a study of 47 patients with lymphoma who had failed prior autologous hematopoietic cell transplantation (HCT), 3-year overall survival was 81% after allogeneic HCT with a conditioning regimen using total lymphoid irradiation and antithymocyte globulin (TLI-ATG). At a median follow up of 4.9 years (range, 2.1-11.9), progression-free survival and non-relapse mortality (NRM) were 44% and 7%, respectively. Among the 25 patients with relapse after allogeneic HCT, 11 (44%) achieved durable (%gt;1 year) complete remission following donor lymphocyte infusion or chemoradiotherapy. The majority of surviving patients (75%; n=24) were able to discontinue all immunosuppression. The researchers concluded that TLI-ATG conditioning followed by allogeneic HCT is a well-tolerated therapy, which produces excellent overall survival and low NRM for patients with relapsed lymphoma after failed autologous HCT.

Rezvani AR, et al. Bone Marrow Transplant

Related Resources